See more : MDB Capital Holdings, LLC Class A common (MDBH) Income Statement Analysis – Financial Results
Complete financial analysis of Herborium Group, Inc. (HBRM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Herborium Group, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Kogi Iron Limited (KFE.AX) Income Statement Analysis – Financial Results
- Novra Technologies Inc. (NVRVF) Income Statement Analysis – Financial Results
- Paradigm Biopharmaceuticals Limited (PBIGF) Income Statement Analysis – Financial Results
- AAEON Technology Inc. (6579.TW) Income Statement Analysis – Financial Results
- RiverNorth Capital and Income Fund, Inc. (RSF) Income Statement Analysis – Financial Results
Herborium Group, Inc. (HBRM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.herborium.com
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics company, develops, licenses, and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. It offers dermatology products, which include AcnEase, herbal medicinal product for enhancing conditions associated with hormonal acne and multiple symptoms of Rosacea; and AcnEase Skin Management System for the treatment of acne marks/scars. The company also provides sexual health and performance products that are non-prescriptive alternatives to selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, and surgical procedures, including hysterectomy. In addition, it offers energy restoration products, such as Lasting Energy, a herbal supplement to decrease the symptoms associated with hangovers and eliminating jet-lag; and for treating overall depletion of energy due to competitive sports, high levels of stress, and extensive sexual activities, as well as other long term or temporary physical demands. Further, the company provides Liver Activator Series for the treatment of liver damage; ProstAid, a natural product focuses on Benign Prostate Hyperplasia; and CardioVitae, a fermentation based product using a Lucidium derived cell line targeting cardio-pulmonary insufficiencies. Herborium Group, Inc. sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. The company was founded in 2000 and is headquartered in Fort Lee, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2007 | 2006 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.12M | 1.13M | 1.05M | 993.50K | 875.00K | 816.30K | 908.60K | 843.20K | 761.88K | 827.76K | 71.47M | 74.33M | 70.33M | 75.01M | 88.87M | 104.94M | 105.43M |
| Cost of Revenue | 495.08K | 430.90K | 389.00K | 354.30K | 365.00K | 338.80K | 348.40K | 313.10K | 381.65K | 295.87K | 67.79M | 69.77M | 65.72M | 69.71M | 81.61M | 96.27M | 98.30M |
| Gross Profit | 624.35K | 702.20K | 662.00K | 639.20K | 510.00K | 477.50K | 560.20K | 530.10K | 380.23K | 531.89K | 3.68M | 4.55M | 4.61M | 5.30M | 7.27M | 8.67M | 7.13M |
| Gross Profit Ratio | 55.77% | 61.97% | 62.99% | 64.34% | 58.29% | 58.50% | 61.66% | 62.87% | 49.91% | 64.26% | 5.15% | 6.13% | 6.56% | 7.07% | 8.18% | 8.26% | 6.76% |
| Research & Development | 35.65K | 30.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.50K | 100.00K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 559.98K | 938.34K | 949.50K | 570.50K | 564.00K | 563.80K | 525.30K | 526.70K | 975.57K | 825.90K | 5.51M | 6.06M | 8.79M | 9.06M | 6.94M | 6.24M | 3.93M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 595.63K | 969.24K | 949.50K | 570.50K | 564.00K | 563.80K | 525.30K | 526.70K | 975.57K | 825.90K | 5.51M | 6.06M | 8.79M | 9.13M | 7.26M | 6.99M | 4.05M |
| Cost & Expenses | 1.09M | 1.40M | 1.34M | 924.80K | 929.00K | 902.60K | 873.70K | 839.80K | 1.36M | 1.12M | 73.31M | 75.84M | 74.50M | 78.84M | 88.86M | 103.26M | 102.35M |
| Interest Income | 808.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 3.20K | 18.10K | 125.10K | 227.30K | 0.00 | 169.30K |
| Interest Expense | 0.00 | 0.00 | 41.27K | 0.00 | 22.00K | 38.00K | 67.00K | 57.80K | 45.66K | 44.75K | 166.20K | 170.50K | 183.70K | 255.80K | 296.00K | 0.00 | 278.60K |
| Depreciation & Amortization | 167.90K | 4.50K | 6.00K | 6.00K | 6.00K | 6.00K | 6.00K | 6.00K | 4.39K | 5.08K | 356.90K | 315.70K | 325.00K | 279.00K | 215.10K | 745.30K | 131.90K |
| EBITDA | 29.52K | -262.54K | -281.50K | 74.70K | -48.00K | -80.30K | 40.90K | 9.40K | -590.95K | -288.93K | -1.48M | -1.19M | -2.01M | -2.39M | 225.30K | 2.43M | 3.21M |
| EBITDA Ratio | 2.64% | -23.17% | -26.78% | 7.52% | -5.49% | -9.84% | 4.50% | 1.11% | -77.56% | -34.91% | -2.09% | -1.59% | -5.73% | -4.73% | -0.01% | 2.53% | 2.85% |
| Operating Income | 28.72K | -267.04K | -287.50K | 68.70K | -54.00K | -86.30K | 34.90K | 3.40K | -595.34K | -294.01K | -1.83M | -1.51M | -4.18M | -3.83M | 10.20K | 1.68M | 3.08M |
| Operating Income Ratio | 2.57% | -23.57% | -27.35% | 6.91% | -6.17% | -10.57% | 3.84% | 0.40% | -78.14% | -35.52% | -2.57% | -2.03% | -5.94% | -5.11% | 0.01% | 1.60% | 2.92% |
| Total Other Income/Expenses | 803.00 | 0.00 | -41.27K | -21.60K | -22.00K | -87.80K | -67.10K | -58.10K | -45.66K | -44.75K | -151.10K | -16.70K | 41.40K | -129.10K | 216.20K | -297.30K | -101.20K |
| Income Before Tax | 29.52K | -267.04K | -328.77K | 47.10K | -76.00K | -174.10K | -32.20K | -54.70K | -641.00K | -338.76K | -1.99M | -1.53M | -4.16M | -3.96M | 226.40K | 1.38M | 2.98M |
| Income Before Tax Ratio | 2.64% | -23.57% | -31.28% | 4.74% | -8.69% | -21.33% | -3.54% | -6.49% | -84.13% | -40.92% | -2.78% | -2.05% | -5.91% | -5.28% | 0.25% | 1.32% | 2.83% |
| Income Tax Expense | -167.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.56K | 1.00K | 57.80K | 617.90K | -1.32M | -1.08M | 104.60K | 557.50K | 1.20M |
| Net Income | 29.52K | -267.04K | -328.77K | 47.10K | -76.00K | -174.10K | -32.20K | -54.70K | -642.56K | -339.76K | -1.89M | -2.13M | -2.84M | -2.85M | 121.80K | 827.30K | 1.78M |
| Net Income Ratio | 2.64% | -23.57% | -31.28% | 4.74% | -8.69% | -21.33% | -3.54% | -6.49% | -84.34% | -41.05% | -2.65% | -2.86% | -4.03% | -3.80% | 0.14% | 0.79% | 1.68% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.68 | -3.13 | -180.47 | -202.99 | -270.47 | -277.31 | 10.00 | 80.00 | 190.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.68 | -3.13 | -180.47 | -202.99 | -270.47 | -277.31 | 10.00 | 80.00 | 186.21 |
| Weighted Avg Shares Out | 10.74B | 9.69B | 8.95B | 6.48B | 6.48B | 6.48B | 5.25B | 2.20B | 113.19K | 108.57K | 10.49K | 10.49K | 10.49K | 10.28K | 10.10K | 10.10K | 9.50K |
| Weighted Avg Shares Out (Dil) | 10.74B | 9.69B | 8.95B | 6.48B | 6.48B | 6.48B | 5.25B | 2.20B | 113.19K | 108.57K | 10.49K | 10.49K | 10.49K | 10.28K | 10.15K | 10.21K | 9.54K |
Herborium® Moves Into Manufacturing Phase For Its New Protein Bars;
Herborium Group progresses with Distribution Agreements for AcnEase® and its Cosmeceuticals to take advantage of $8Billion French Cosmetic Market;
Herborium® Targets $6.5 Billion French Amazon Market for its unique AcnEase® Botanical Therapeutic® and its New Skin Protein Bar
Herborium® Targets Distribution of its New Skin Protein Bar by Whole Foods, TraderJoe, Walmart and Target the Fall 2021
Herborium Sales for First Quarter 2021 rises 20% Debt decreased $500.000
Herborium Moves to the Next Level in Building a Disruptive, Integrated, Natural Medicine Content and Commerce Platform
Herborium® Group Inc. Skin Health Products to Enter $250 Million Pacific Asian Market
Herborium Group Introduces Proprietary Two- in- One Biodegradable, Multi-Use Facial Mask
Herborium® Group Inc, Shareholders Update Letter
Source: https://incomestatements.info
Category: Stock Reports